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P R E D I C T I V E V A L U E OF R E A L - T I M E RIGISCAN MONITORING FOR 
T H E E T I O L O G Y OF ORGANOGENIC I M P O T E N C E 
M O H A M A D D J A M I L I A N , C H R I S T I A N G. STIEF, U . H A R T M A N N A N D UDO JONAS 
From the Departments of Urology and Psychological Medicine, Medizinische Hochschule Hannover, Medical School, Hannover, Germany 
A B S T R A C T 
We performed routine diagnostic evaluations i n 160 consecutive patients from our impotence 
clinic. After the diagnostic studies were completed, the results of RigiScan* monitoring during visual 
sexual stimulation before and after intracavernous injection of vasoactive drugs were compared to 
the results of standardized pharmacological testing, single potential analysis of cavernous electrical 
activity and pharmacocavernosometry. The results suggest RigiScan monitoring to be a highly 
accurate method to evaluate and document objectively the erectile response after intracavernous 
injection of vasoactive drugs. Although pathological monitoring after intracavernous injection is 
significantly associated wi th pathological findings i n the specific evaluation, the predictive value of 
RigiScan monitoring for specific organogenic etiologies is not satisfactory, since normal monitoring 
showed no convincing correlation to single potential analysis of cavernous electrical activity or 
cavernosometry. 
K E Y W O R D S : impotence, penile erection, evoked potentials, pharmacology 
The first objective diagnostic approach that was believed to 
differentiate psychogenic and organogenic impotence was the 
introduction of nocturnal penile tumescence measurements.1 
Popularized in the mid 1960s, this method was the standard 
evaluation in the etiological differentiation of organogenic and 
psychogenic factors. During the years this approach was refined 
by simultaneous registration of penile tumescence and rigidity. 2 
Recent neurophysiological studies are casting some doubts 
about the basic assumption that nightly erections are com-
parable with erections needed for intercourse and that, there-
fore, good nighttime erections should exclude organogenic fac-
tors for erectile dysfunction. In these neurophysiological studies 
there is strong evidence that nighttime erections may be differ-
ent from erection during sexual arousal regarding the neurolog-
ical input. 3 However, other recent studies suggest that real-
time monitoring of penile tumescence and rigidity during visual 
sexual stimulation may be helpful in the differential diagnosis 
of psychogenic versus organogenic impotence.4 We evaluate 
whether real-time monitoring of penile tumescence and rigidity 
during visual sexual stimulation before and after intracav-
ernous injection of vasoactive drugs may be helpful in the 
differentiation of organogenic impotence. 
P A T I E N T S A N D M E T H O D S 
A total of 160 consecutive patients from our impotence clinic 
entered this study. Since we routinely use intracavernous injec-
tions of vasoactive drugs in the diagnostic evaluation we ex-
cluded patients with arterial occlusive disease of stages 3 and 
4, cardiac arrhythmias, recent myocardial infarction, sexual 
deviation, severe psychogenic disorders, addiction, severe liver 
insufficiency and age greater than 65 years. The diagnostic 
evaluation in every patient included history (with an emphasis 
on sexual function) with the aid of a standardized question-
naire, physical examination and blood chemistry studies (SMA-
12, testosterone and prolactin levels).5 History, sexual history 
and partner interview were then obtained by a psychiatrist, and 
psychological testing was done by a clinical psychologist. Single 
potential analysis of cavernous electric activity (SPACE) was 
registered with the frequency range set at 0.5 to 100 Hz.6 A 
standardized diagnostic injection of a vasoactive drug mixture 
Accepted for publication August 28, 1992. 
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(3 mg. papaverine hydrochloride and 0.1 mg. phentolamine 
mesylate) was given and the erectile response was evaluated by 
a urologist.5 To enhance reproducibility the patient was advised 
to refrain from psychological or reflexogenic stimulation. De-
pending on the erectile response the dose was decreased, un-
changed or augmented for the following injection (with at least 
a 24-hour interval) and at least 3 injections were administered. 
Real-time monitoring of penile tumescence and rigidity was 
done with a RigiScan device.2 After explanation of the diagnos-
tic procedure and its possible relevance to the patient, and 
installation of the device the patient was exposed to a sexually 
explicit video for 30 minutes. Then, intracavernous injection 
of 3 mg. papaverine and 0.1 mg. phentolamine was done, and 
the recording (with video) was repeated for 30 minutes. Of 160 
patients 53 underwent pharmacocavernosometry and pharma-
cocavernosography. This unusually high number is due to nu-
merous patients in the extensive study for penile revasculari-
zation. 
The results of the Doppler examination7 were not included 
in this study, since the discussion about its significance is not 
finished. Results regarded as pathological included standard-
ized, repeated intracavernous injections with an incomplete 
erectile response to doses greater than 7.5 mg. papaverine and 
0.25 phentolamine;5 SPACE showing repeated abnormal poten-
tials, repeated desynchronization of both cavernous bodies and 
repeated positive or negative sharp waves;6 RigiScan monitor-
ing showing a penile rigidity of less than 70%2 with at least 1 
phase of 70% of at least 5 minutes to be classified as normal, 
and pharmacocavernosometry results showing a maintenance 
flow of 20 ml. per minute or more.8"10 Statistical analysis was 
done with the chi-square test and Pearson's correlation test. 
R E S U L T S 
In 12 patients (7.5%) RigiScan monitoring during audiovisual 
sexual stimulation showed a penile rigidity of 70% or more, 
while 148 (92.5%) had a rigidity of less than 70%. After in-
tracavernous injection of the vasoactive drug mixture the for-
mer 12 patients and 96 of the latter 148 patients (60%) showed 
a rigidity of 70% or more during visual sexual stimulation, 
while the remaining 52 (32.5%) still had a penile rigidity of less 
than 70%. Of the 12 patients with normal monitoring before 
and after intracavernous injection 6 showed no abnormal find-
ings in the other diagnostic procedures and 6 showed 1 abnor-
mal result. Of the 96 patients with abnormal monitoring before 
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and normal monitoring after intracavernous injection 42 (44%) 
showed no abnormal findings during examination. All patients 
with abnormal monitoring before and after intracavernous 
injection had at least 1 abnormal result during the diagnostic 
evaluation. 
The 12 patients with normal RigiScan monitoring before and 
after intracavernous injection had a full erectile response to 
pharmacological testing, compared to 74 of the 96 (77%) with 
abnormal monitoring before and normal monitoring after in­
tracavernous injection. The remaining 22 of the 96 patients 
(23%) had an incomplete erection on pharmacological testing. 
These 22 patients underwent cavernosometry: 18 showed an 
abnormal and 4 a normal maintenance flow. All 52 patients 
with abnormal monitoring results before and after intracav­
ernous injection had abnormal pharmacological testing re­
sponses. Of the 160 patients overall 138 (86%) showed com­
parable results for erectile response when evaluated by Rigi­
Scan monitoring or by a urologist (see table). 
Of the 12 patients with normal RigiScan monitoring during 
visual sexual stimulation, 6 had normal and 6 had abnormal 
SPACE findings, compared to 62 (65%) and 34 (35%), respec­
tively, of the 96 patients with abnormal monitoring before and 
normal monitoring after intracavernous injection, and 9 (17%) 
and 43 (83%), respectively, of the 52 patients with abnormal 
monitoring before and after intracavernous injection (see 
table). Of the 53 patients undergoing pharmacocavernosometry 
16 had a normal and 37 had an abnormal maintenance flow. 
The 2 patients in this group with normal RigiScan monitoring 
on visual sexual stimulation showed no venous leakage. No 
venous leakage was noted in 9 of the 27 patients (33%) with 
abnormal monitoring before and normal monitoring after in­
tracavernous injection, and in 5 of the 24 (21%) with abnormal 
monitoring before and after intracavernous injection, while 
venous leakage occurred in 18 (67%) and 19 (79%), respectively. 
D I S C U S S I O N 
Only 12 of 160 patients (7.5%) showed a RigiScan monitoring 
of 70% or more in response to visual sexual stimulation. This 
figure of a normal erectile response to audiovisual sexual stim­
ulation seems to be low, especially because 48 of 160 patients 
had no abnormal findings on pharmacological testing, SPACE 
or cavernosometry. Since all of these patients with no abnormal 
findings in the evaluation had normal RigiScan monitoring to 
audiovisual sexual stimulation after an intracav­
ernous injection of a minimal dose of vasoactive drugs (and 
only 6 of them before the injection), this reduced erectile 
response to audiovisual sexual stimulation before intracaver­
nous injection may be explained by psychogenic inhibition. 1 1 , 1 2 
The psychogenic inhibition may be evoked by the examination 
itself, the rigidity recording device, the video or many other 
factors that stress the patient. As shown in dogs, only small 
Results of RigiScan monitoring versus pharmacological testing, SPACE 
and pharmacocavernosometry in 160 patients 
RigiScan Monitoring 
Normal/ Abnormal/ Abnormal/ 
Normal Normal Abnormal 
Pharmacological testing:* 
Normal 12 74 0 
Abnormal 0 22 52 
S P A C E : t 
Normal 6 62 9 
Abnormal 6 34 43 
Pharmacocavernosometry: $ 
Normal 2 9 5 
Abnormal 0 18 19 
* Chi-square 91.73, 2 degrees of freedom, ρ <0.001. Pearson's R = 0.72, ρ 
<0.001. 
t Chi-square 30.21, 2 degrees of freedom, ρ <0.001. Pearson's R = 0.35, ρ 
<0.001. 
t Chi-square 5.75, 2 degrees of freedom, ρ = 0.06. Pearson's R = 0.27, ρ = 0.03. 
amounts of norepinephrine, without systemic effects, may sig­
nificantly influence the erectile response.12 This elevated sym­
pathetic tone induces cavernous smooth muscle contraction, 
thereby decreasing the erectile response to audiovisual sexual 
stimulation. These results suggest that even patients with a 
normal erectile capacity may not respond to audiovisual sexual 
stimulation with a full erection. To avoid these false-negative 
results, a minimal dose of vasoactive drugs should be given 
before real-time RigiScan monitoring. 
Furthermore, we have requested a minimum of 5 minutes of 
70% rigidity (according to the RigiScan scale) to classify the 
erectile response as normal. This 5-minute period was requested 
because a brief increase in penile rigidity may be due to either 
palpation of the penis by the patient or squeezing of the pelvic 
floor by the device during measurement of rigidity. This pre­
requisite of at least 5 minutes of 70% rigidity may also have 
contributed to the low figure of 7.5% normal erections to audio­
visual sexual stimulation. In our series the unspecific predictive 
value of real-time RigiScan monitoring regarding the outcome 
of any specific investigations was low when monitoring showed 
a normal response before and/or after intracavernous injection. 
However, when monitoring showed abnormal results before 
and after intracavernous injection specific investigations re­
vealed at least 1 abnormal finding in all patients. 
Real-time RigiScan monitoring showed a high correlation 
with the erectile response to pharmacological testing. The chi-
square test and Pearson's correlation indicate a high correlation 
of both variables. In 86% of the patients RigiScan monitoring 
to visual sexual stimulation after intracavernous injection re­
vealed a comparable erectile response than that evaluated by a 
urologist after pharmacological testing. In the remaining 14% 
of the patients RigiScan monitoring indicated a better erectile 
response than the response evaluated by the urologist. This 
discrepancy may be easily explained by the additional psycho­
genic (and perhaps by the recording device itself, even reflex-
ogenic) stimulation applied with intracavernous injection dur­
ing RigiScan monitoring, compared to intracavernous injection 
alone for pharmacological testing. This additional stimulation 
is most likely responsible for most of the increased rate of 
patients with better results in RigiScan monitoring compared 
to pharmacological testing. Furthermore, 18 of these 22 patients 
showed venous leakage, obviously moderate to mild, since phar­
macological relaxation plus psychogenic stimulation induced a 
sufficient erectile response. These figures suggest that RigiScan 
monitoring is a highly accurate and objective measuring device 
for erectile response to intracavernous injections of vasoactive 
drugs. 
Of 12 patients with a normal response to visual sexual 
stimulation on RigiScan monitoring 6 had pathological findings 
on SPACE. This finding strongly suggests that, to a certain 
extent, disturbances of the autonomic cavernous supply may 
still be associated with a functionally sufficient penile hemo­
dynamic response. This assumption correlates well with the 
findings of Walsh et al, who observed that even after unilateral 
iatrogenic disruption of the cavernous nerve the erection may 
still be sufficient for intercourse.13 Further studies are needed 
to reveal the critical extent of abnormal SPACE findings that 
are still associated with a sufficient erection. 
The specific predictive value of RigiScan monitoring for 
SPACE was low when monitoring showed a normal response 
before and/or after intracavernous injection (although after 
intracavernous injection more patients with normal monitoring 
show normal SPACE findings and vice versa). However, when 
the monitoring was abnormal before and after intracavernous 
injection abnormal SPACE findings were obtained in 83% of 
the patients. This correlation of RigiScan and SPACE findings 
is statistically significant but quantitatively limited. Therefore, 
this correlation seems to be of no or only limited clinical 
significance. 
The specific predictive value of RigiScan monitoring for 
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venous leakage seems to be low, since only a third of the 
patients with normal monitoring after intracavernous injection 
had no venous leakage but two-thirds had venous leakage. This 
finding may be explained by the fact that venous leakage is a 
gradual phenomenon, from just above normal to excessive. Low 
or moderate venous leakage may well be compensated by ad­
ditional arterial inflow, as shown in the animal. This compen­
sation results in normal RigiScan monitoring in the presence 
of venous leakage. However, pathological monitoring after in­
tracavernous injection is associated in 79% of the cases with a 
venous leak. Statistically, the correlation of RigiScan monitor­
ing and cavernosometry is on the edge of significance. This 
limited correlation of both variables seems to be of no clinical 
significance as shown previously. 
Our results strongly suggest RigiScan monitoring to be a 
highly accurate method of evaluating and objectively docu­
menting the erectile response after intracavernous injection of 
vasoactive drugs. Although pathological monitoring after in­
tracavernous injection is significant^ associated with patho­
logical findings in the specific evaluation, the predictive value 
of RigiScan monitoring for specific organogenic etiologies is 
not satisfactory, since normal monitoring showed no clinically 
significant correlation to SPACE or cavernosometry. Cur­
rently, RigiScan monitoring seems not to be able to replace 
specific diagnostic investigations. As soon as valid parameters 
for arterial diagnosis are well established their correlation to 
RigiScan monitoring should be examined. 
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